Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
30 studies found for:    melanoma | Open Studies | interleukin-2
Show Display Options
RSS Create an RSS feed from your search for:
melanoma | Open Studies | interleukin-2
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and Nerve Growth Factor Receptor (NGFR) Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
2 Recruiting Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Procedure: Translational research;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Interleukin-2;   Drug: Ipilimumab infusion
3 Recruiting Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Condition: Metastatic, Stage III or Stage IV, Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor-Infiltrating Lymphocytes;   Biological: Low-Dose Interleukin
4 Recruiting Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T-Cells;   Biological: Interleukin-2;   Drug: Mesna;   Biological: Intrathecal T-Cells;   Biological: Intrathecal Interleukin-2
5 Recruiting T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T cells;   Biological: Interleukin-2;   Biological: Dendritic cell vaccine
6 Recruiting Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Condition: Metastatic Melanoma
Interventions: Other: Radiation therapy and high-dose IL-2;   Drug: High-dose IL-2
7 Recruiting Tumor Infiltrating Lymphocytes (TIL) Transduced With TGFbDNRII
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
8 Not yet recruiting TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: Tumour Infiltrating Lymphocytes;   Drug: Interleukin-2
9 Recruiting MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine;   Procedure: TIL (T-cells);   Drug: IL-2;   Drug: MK-347;   Behavioral: Questionnaires;   Behavioral: Phone Calls
10 Recruiting Vemurafenib and TIL Therapy for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vemurafenib;   Drug: Lymphodepleting chemotherapy;   Drug: TIL infusion;   Drug: Interleukin-2
11 Recruiting Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Procedure: CD8+ T Cells;   Drug: Interleukin-2;   Drug: Ipilimumab
12 Recruiting Peginterferon and TIL Therapy for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL infusion;   Drug: Interleukin-2;   Drug: Peginterferon alfa-2b
13 Recruiting Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients
Condition: Metastatic Melanoma
Intervention: Drug: Proleukin and Dacarbazine
14 Not yet recruiting Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Metastatic Melanoma;   Stage III Mucosal Melanoma of the Head and Neck;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma;   Stage IVA Mucosal Melanoma of the Head and Neck;   Stage IVB Mucosal Melanoma of the Head and Neck;   Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
15 Not yet recruiting A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Condition: Melanoma
Intervention: Drug: High dose bolus interleukin-2 (HD IL2)
16 Recruiting Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Conditions: Melanoma (Skin);   Skin Cancer
Interventions: Drug: Nivolumab;   Procedure: Surgery to Remove Tumor for Growth of TIL;   Drug: CD137;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: TIL Infusion;   Drug: Interleukin-2
17 Recruiting Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: High Dose Interleukin-2 (IL-2);   Procedure: ACT with TIL Infusion;   Drug: Vemurafenib;   Drug: Lymphodepletion
18 Not yet recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
19 Recruiting Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2
Conditions: Metastatic Renal Cell Cancer;   Malignant Melanoma, Metastatic
Intervention: Other: Boost of radiotherapy + high dose IL-2 treatment
20 Recruiting Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells;   Drug: non-myeloablative conditioning chemotherapy

   Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results    Last Page
Indicates status has not been verified in more than two years